Chief Executive Officer
Tommi has been running Blueprint Genetics since the beginning and is responsible for sales management, business development, finance and administration. He visits Bay Area frequently and attends life science and diagnostics events regularly. Tommi holds a M.Sc. from the Helsinki University of Technology where he studied business strategy and applied mathematics.
Laboratory Director, Chief Medical Officer, MD, Ph.D.
Juha is supervising laboratory production and is responsible for designing new diagnostic tests. He participates on a daily basis in clinical evaluation of the genetic findings and further develops variant classification and interpretation practices in the company in collaboration with a team of geneticists. Juha is a co-founder of Blueprint Genetics. Juha has a MD-PhD from the University of Turku, he finished the fellowship program in clinical physiology and nuclear medicine in 2006, and became a docent in the following year. During 2007-2009, he joined the UCSF Cardiac Stem Cell Translational Development Program (California, USA) as a post-doctoral researcher and later as a research specialist. He is also working as a professor at the University of Helsinki.
President, Chief Medical Officer, MD, Ph.D.
Tero-Pekka is the Chief Medical Officer and President of Blueprint Genetics Inc. He is based in San Francisco and in charge of the operations in North America. He is also designing diagnostic panels, mutation databases and works with clinical evaluation of genetic data. Tero-Pekka is a co-founder of Blueprint Genetics. Tero-Pekka has a MD-PhD degree and is specialized in pediatrics and pediatric cardiology. Tero-Pekka has a PhD in molecular and cellular biology. In 2007 he continued his research at Stanford University, School of Medicine. During this 3-year postdoctoral training he focused on the molecular genetic mechanisms of cardiovascular diseases. He continued his cardiovascular research at the University of Helsinki as a principal investigator and the head of an academic research group.
Chief Technology Officer, Ph.D.
Samuel is the Head of R&D and Operations at Blueprint Genetics. Samuel is an expert in genome analysis technologies and has wide experience in bioinformatics and cancer genomics research. Samuel received his PhD from the University of Helsinki and did his post-doctoral research in Stanford University where he developed high-throughput sequencing technologies, such as the Oligonucleotide-Selective Sequencing (OS-Seq™). He is an Adjunct Professor in Genetics (University of Helsinki), an author of several high-impact publications and an inventor in patents of DNA sequencing methods. Samuel is a co-founder of Blueprint Genetics.
Board of directors
Ville Koskenvuo is Partner at Vaaka Partners, which is a Finnish midmarket private equity firm. Before Vaaka Partners he worked at EQT where he focused on European healthcare and medical device buyout investments, and has vast experience from Boards of EQT-owned medical device companies like CaridianBCT, Gambro and HTL-Strefa. Ville Koskenvuo holds a M.Sc. (Tech.) degree from Helsinki University of Technology.
Tuomas Kosonen, is Partner at Inventure, which is a leading Finnish venture capital investor with approximately €120 million in committed equity capital. In his work at Inventure he is focused on Nordic software and healthcare venture investments, and has a wide experience from working in different boards in the Nordics and US. Tuomas Kosonen holds a M.Sc.(Econ and Law) degree from Aalto University.
Erik has over 20 years of experience in the medical device and pharmaceutical world. He has worked for leading companies like Abbott and bioMerieux, and has an extensive experience in sales, marketing, management, as well as head of a division including R&D. Erik is currently COO at Sebia, world leader in electrophoresis.
Brock Siegel, PhD is an investor and advisor to seed-stage life science ventures, working through investment groups including BioInflexion Point Partners, Life Science Angels and QB3 Mission Bay Capital Fund. He currently serves on the Board of Directors of Mission Bio Inc, Rapid Diagnostek Inc and the Addario Lung Cancer Medical Institute, and on the Advisory Board of Cue Diagnostics Inc. Brock has been a senior executive with Henkel KGaA, Millipore, BioSearch, Applied Biosystems, Solexa, Illumina, Complete Genomics, Moleculo and Zephyrus Bio, focusing his career on bio-tool, diagnostic and applied markets products, especially NGS sequencing and qPCR.
Senior Advisor, PhD
Gary Zweiger, PhD, is a business development professional, consultant, investor, and advisor in the life sciences, with a focus on DNA sequencing, genetic testing, and molecular diagnostics. He has supported numerous innovative companies in developing partnerships, licensing, fundraising, M&A, market development, and strategy. He has held leadership positions in business development at Purigen Biosystems, Moleculo (sold to Illumina), Affymetrix, Life Technologies, and Agilent Technologies. He holds a BS in Biological Sciences and a PhD in Genetics from Stanford University, completed post-doctoral studies at Genentech, and is the author of a popular science book on the race to sequence the human genome (Transducing the Genome, McGraw-Hill, 2001).
Senior Advisor, PhD
John Quackenbush received his PhD in theoretical physics from UCLA in 1990. Following a physics postdoc, he received a Special Emphasis Research Career Award from the National Center for Human Genome Research to work on the Human Genome Project, spending two years at the Salk Institute and two years at Stanford University working in genomics and computational biology. In 1997 he moved to The Institute for Genomic Research (TIGR), pioneering expression analysis. He joined the Dana-Farber Cancer Institute and the Harvard School of Public Health in 2005. In 2012, he and Mick Correll founded Genospace, a precision medicine software company.
Scientific Advisor, MD, PhD
Juha Kere, MD, PhD, is professor of molecular genetics at Karolinska Institutet, Stockholm, Sweden. His research interests are broad, including complex disorders, such as asthma, psoriasis and dyslexia, and most recently, single-cell gene expression analysis to understand cellular functions. He has published over 400 original and review articles and served in expert and advisory roles for many organisations. Prior to moving to Karolinska Institutet, he served as the Founding Director of Finnish Genome Center in Helsinki